Business Wire

IDEMIA Appoints Pierre Barrial as President & Chief Executive Officer of the Group

30.6.2020 09:00:00 EEST | Business Wire | Press release

Share

The supervisory board of IDEMIA has appointed Pierre Barrial as the new President & CEO of the Group, replacing Yann Delabrière who resumes his previous role as Chairman of the Board. Matthew Cole, who has joined the Group, has taken on Pierre Barrial’s previous position as head of the Secure Enterprise Transactions (SET) division.

Over the last 18 months, IDEMIA has restored its growth and cash generation performance after the creation and successful integration of IDEMIA. Yann, who became President & CEO on October 18th 2018, will now be returning to his role as Chairman of the Board with effect from July 1st, 2020, where he will continue to contribute his strategic and governance insights to the company.

Pierre Barrial will succeed Yann as the Group’s President & CEO. He brings over 25 years’ experience with multinational and multicultural tech companies serving both the government and enterprise sectors. Pierre was in charge of SET, having previously managed IDEMIA’s Mobile Operators then Financial Institutions activities, both today part of the SET division. He has partnered with Yann since the beginning of the year as Deputy CEO. Pierre will become IDEMIA’s Group President & CEO starting July 1st, 2020.

Matthew Cole is appointed as head of the SET division, replacing Pierre Barrial. Matthew brings a wealth of experience in this space, having been President of Cubic Transportation Systems, the leading integrator of payment and information solutions and related services for intelligent travel applications in the transportation industry. He will be based in the US and will sit on the Group Executive Committee, as SET division’s CEO.

Yann Delabrière stated: “After a carefully prepared succession plan, we have chosen a world-class executive, Pierre Barrial, to manage the Group. IDEMIA has demonstrated remarkable resilience since the beginning of this year and our business fundamentals are strong and bode well for the future. On behalf of the Board, I wish Pierre all the very best in his new role.”

Pierre Barrial added: “I’m honored and excited to have been chosen as CEO of the Group. IDEMIA has an extremely committed team of 15,000 employees worldwide and together, we’ll continue to serve our clients regardless of the circumstances. I am also proud to head a company whose purpose, since its creation, is to make the world a safer place, whenever and wherever Identity & Security matter in an increasingly digital world. With recent events, this is more true than ever.”

Matthew Cole said: “I am thrilled and proud to join IDEMIA as CEO of the SET division. I plan to work hand in hand with my teams and Group senior management to bring the company’s strategy and growth targets to fruition.”

About Yann Delabrière
Yann Delabrière is a graduate of Ecole Normale Supérieure and Ecole Nationale d’Administration and has a postgraduate degree in mathematics. He began his career at the Committee of Public Accounts (Cour des Comptes) before working for the French External Trade Minister. He then became Chief Financial Officer for the French export credit agency, COFACE, followed by Printemps Group, before becoming Chief Financial Officer for PSA Peugeot Citroën in 1990 and, from 1998, was Chairman and Chief Executive Officer of Banque PSA Finance and sat on the PSA Peugeot Citroën Executive Committee. In 2007 Yann was appointed Chairman and Chief Executive Officer of Faurecia. From June 2017 to February 2018, he chaired the Zodiac Aerospace executive board. From 2004 to May 2018 he was a director of Cap Gemini, from 2012 to 2016 a director of Société Générale and since March 2017 has been a director of Alstom. He has chaired the IDEMIA executive board since October 2018 having previously chaired the IDEMIA supervisory board for a 10-month period.

About Pierre Barrial
Pierre Barrial graduated from Paris School of Business. He comes with over 25 years experience with multinational and multicultural firms and agencies from a broad array of industries including ICT and security, serving both the public and private sectors. After Pierre joined IDEMIA in 2013, he managed the Group’s Latin American operations followed by the Mobile Operators business, the Financial Institutions business and SET. Previously, Pierre worked in various jobs for Bull Group in South Africa, Italy, Poland and Brazil.

About Matthew Cole
Matthew Cole holds an MBA from Oxford Brookes University and is also Chartered Certified Accountant. In 2003 he joined Cubic Corporation, the world leader in smart and contactless payments for transportation. During his time at Cubic Matthew held several senior finance positions before successfully heading up the company’s Asia-Pacific operations followed by global Strategy and Business Development. In 2015, he became President of Cubic Transportation Systems. Before Cubic Corporation, Matthew held several positions with blue-chip multinational firms including Endemol, British Airways, Mitsui, First Choice and Schlumberger.

About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Hanna Sebbah
idemia@havas.com
+33 (0) 6 63 73 30 30

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release

SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release

Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye